ImmunityBio (IBRX) Loses 17% to Profit-Taking After Intra-Day High

We recently published 10 Stocks Left Behind in a Roaring Market. ImmunityBio Inc. (NASDAQ:IBRX) was one of the worst performers on Wednesday.

ImmunityBio finished the session down sharply on Wednesday, as investors resorted to profit-taking after touching a new record high during the day.

At intra-day trading, ImmunityBio Inc. (NASDAQ:IBRX) soared to its highest price of $12.43 before giving up all gains to finish the day down by 17.40 percent at $9.54 apiece.

The profit-taking followed the company’s strong financial and operating highlights last year, with total revenues expanding by 671 percent to $113 million from only $14.7 million in 2024.

Total revenues were supported by a 700 percent jump in net product revenues, thanks to a 750 percent sales volume expansion from its bladder cancer treatment, Anktiva.

However, ImmunityBio Inc. (NASDAQ:IBRX) remained at a net loss attributable to shareholders of $351.4 million, albeit narrower by 15 percent than the $413.56 million in 2024.

In the fourth quarter alone, revenues increased by 407 percent to $38.28 million from $7.5 million year-on-year, while attributable net loss increased by 4.6 percent to $61.9 million from $59.16 million year-on-year.

Optimism was further bolstered by a series of regulatory approvals earlier, paving the way for ImmunityBio Inc.’s (NASDAQ:IBRX) sales expansion of Anktiva in 33 international markets, including the United Kingdom, European Union members, and Saudi Arabia.

Three other clinical trials are planned over the next three years to test Anktiva’s efficacy in other therapeutic areas, including its use alongside standard-of-care treatments, CAR-NK / M-ceNK, and in treating lymphopenia.

While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.